Does a single nucleotide polymorphism in the FGFR explain the connection between diabetes and cancer?

Emily J Gallagher; Derek LeRoith

doi:10.1016/j.cmet.2013.05.006

Does a single nucleotide polymorphism in the FGFR explain the connection between diabetes and cancer?

Cell Metab. 2013 Jun 4;17(6):808-809. doi: 10.1016/j.cmet.2013.05.006.

Authors

Emily J Gallagher¹, Derek LeRoith²

Affiliations

¹ Division of Endocrinology, Diabetes & Bone Disease and the Diabetes, Obesity, Metabolism Institute, Icahn School of Medicine at Sinai, 1 Gustave L. Levy Place, Atran 4(th) floor-36, Box 1055, New York, NY 10029-6574, USA.
² Division of Endocrinology, Diabetes & Bone Disease and the Diabetes, Obesity, Metabolism Institute, Icahn School of Medicine at Sinai, 1 Gustave L. Levy Place, Atran 4(th) floor-36, Box 1055, New York, NY 10029-6574, USA. Electronic address: derek.leroith@mssm.edu.

PMID: 23747238
DOI: 10.1016/j.cmet.2013.05.006

Abstract

A polymorphism in the fibroblast growth factor receptor 4 gene has been associated with cancer progression and treatment resistance and is now reported to increase insulin secretion, providing a possible genetic link between hyperinsulinemia and cancer (Ezzat et al., 2013).

Publication types

Comment

MeSH terms

Adaptor Proteins, Signal Transducing
Animals
Humans
Insulin / metabolism*
Insulin Secretion
Proteins / metabolism*
Receptor, Fibroblast Growth Factor, Type 4 / metabolism*
STAT3 Transcription Factor / metabolism*
STAT5 Transcription Factor / metabolism*

Substances

Adaptor Proteins, Signal Transducing
Grb14 protein, mouse
Insulin
Proteins
STAT3 Transcription Factor
STAT5 Transcription Factor
Stat3 protein, mouse
Fgfr4 protein, mouse
Receptor, Fibroblast Growth Factor, Type 4